BlackRock, Inc. 13D and 13G filings for Fulcrum Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale | 2025-03-31 | 13G | Fulcrum Therapeutics, Inc. FULC | BlackRock Inc. BLK | 4,032,876 7.500% | -1,542,440 (-27.67%) | Filing |
| 2024-12-06 4:28 pm Sale | 2024-11-30 | 13G | Fulcrum Therapeutics, Inc. FULC | BlackRock Inc. BLK | 5,575,316 10.300% | -131,304 (-2.30%) | Filing |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Fulcrum Therapeutics, Inc. FULC | BlackRock Inc. BLK | 5,706,620 9.100% | 0 (Unchanged) | Filing |
| 2024-10-21 4:11 pm Purchase | 2024-09-30 | 13G | Fulcrum Therapeutics, Inc. FULC | BlackRock Inc. BLK | 5,706,620 9.100% | 4,192,195 (+276.82%) | Filing |
| 2023-07-07 4:35 pm Sale | 2023-06-30 | 13G | Fulcrum Therapeutics, Inc. FULC | BlackRock Inc. BLK | 1,514,425 2.500% | -1,754,566 (-53.67%) | Filing |
| 2023-02-01 4:54 pm Purchase | 2022-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC | BlackRock Inc. BLK | 3,268,991 6.300% | 1,060,913 (+48.05%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC | BlackRock Inc. BLK | 2,208,078 5.400% | 2,208,078 (New Position) | Filing |